These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 20545481)

  • 1. Targeting YAP and Hippo signaling pathway in liver cancer.
    Liu AM; Xu MZ; Chen J; Poon RT; Luk JM
    Expert Opin Ther Targets; 2010 Aug; 14(8):855-68. PubMed ID: 20545481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis.
    Patel SH; Camargo FD; Yimlamai D
    Gastroenterology; 2017 Feb; 152(3):533-545. PubMed ID: 28003097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippo signaling regulates pancreas development through inactivation of Yap.
    George NM; Day CE; Boerner BP; Johnson RL; Sarvetnick NE
    Mol Cell Biol; 2012 Dec; 32(24):5116-28. PubMed ID: 23071096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung.
    Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA
    J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
    Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
    PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
    Wong KF; Liu AM; Hong W; Xu Z; Luk JM
    Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer.
    Chen M; Zhang H; Shi Z; Li Y; Zhang X; Gao Z; Zhou L; Ma J; Xu Q; Guan J; Cheng Y; Jiao S; Zhou Z
    J Biol Chem; 2018 Sep; 293(37):14455-14469. PubMed ID: 30072378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippo signaling pathway in companion animal diseases, an under investigated signaling cascade.
    Budel SJ; Penning MM; Penning LC
    Vet Q; 2021 Dec; 41(1):172-180. PubMed ID: 33945400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
    Hao Y; Chun A; Cheung K; Rashidi B; Yang X
    J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippo-YAP signaling pathway: A new paradigm for cancer therapy.
    Ma Y; Yang Y; Wang F; Wei Q; Qin H
    Int J Cancer; 2015 Nov; 137(10):2275-86. PubMed ID: 25042563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippo signaling promotes JNK-dependent cell migration.
    Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.